Application
| WB, ICC |
|---|---|
| Primary Accession | P04637 |
| Other Accession | NP_000537.3 |
| Host | Rabbit |
| Reactivity | Human |
| Clonality | Polyclonal |
| Description | Rabbit Anti-Human p53 Polyclona |
| Target/Specificity | Predicted molecular weight at ~43.7kDa. Observed bands at ~53kDa. |
| Other Names | TP53 Antibody, Tumor Protein 53 Antibody, BCC7 Antibody, LFS1 Antibody, TRP53 Antibody, p53 tumor suppressor Antibody |
| Immunogen | Synthetic peptide from the C-terminal of human tumor protein p53. |
| Purification | Peptide Affinity Purified |
| Storage | -20ºC |
| Storage Buffer | PBS, 50% glycerol, 0.09% sodium azide |
| Shipping Temperature | Blue Ice or 4ºC |
| Certificate of Analysis | A 1:1000 dilution of SPC-682 was sufficient for detection of p53 on HeLa cell lysates using Goat anti-rabbit IgG:HRP as the secondary antibody. |
| Cellular Localization | Cytoplasm | Nucleus | PML body | Endoplasmic Reticulum | Mitochondrion matrix |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@clinisciences.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The p53 protein (tumor protein 53 or TP53) is a DNA-binding cell cycle-regulating transcription factor that governs cell division and the fine balance between cell death and cell survival (1). P53 plays a critical role in tumor suppression and hence it is often described as "the guardian of the genome", "the guardian angel gene", or the "master watchman." This also refers to its role in conserving stability by preventing genome mutation (2). Defects in p53 are linked to >50% of human cancers, and restoring p53 function to these cancer cells can induce growth arrest and apoptosis (3). When p53 has been damaged, it can also lead to autoimmune disorders (4, 5).
References
1. Georescu C.V., Saftoiu A., Georgescu C.C., Ciurea R. and Ciurea T. (2007) J Gastrointestin Liver Dis. 16(2): 133-9.
2. Strachan T., et al. (1999) Human Molecular Genetics 2. Ch. 18: Cancer Genetics.
3. Hansen J.E., et al. (2007) Cancer Research 67: 1769-1774.
4. Di Cesare E., et al. (2001) Ann Clin Lab Sci 31: 253-8.
5. Akere A., Otegbayo J.A. (2007) Singapore Med J. 48(1): 41-4.